Bradley Merrill Thompson, a Member of the Firm in the Health Care and Life Sciences practice, in the Washington, DC, office, was quoted in an article titled "Sebelius Departure from HHS will have Negligible Effect on HIT."
Following is an excerpt:
With all the problems that have plagued the rollout and operation of the federal exchange website Healthcare.gov, the announcement that Kathleen Sebelius has decided to resign as Secretary of Health and Human Services makes perfect sense. Sebelius is trying to leave on a "high note," timing her resignation with the end of open enrollment on March 31, which marked the milestone of an estimated 7.5 million Americans having signed up for healthcare coverage under the Affordable Care Act. ...
Her time at HHS was focused on healthcare reform, for obvious reasons. Unfortunately it meant that she had little time for FDA or for health information technology," says Bradley Merrill Thompson, an attorney at the law firm Epstein Becker Green, who counsels medical device companies on FDA regulatory issues. "While the Affordable Care Act is extraordinarily important, my hope is that the next secretary will be able to be a bit more balanced, investing time in making sure that the work of the FDA gets done appropriately, and in a timely way."
